<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00925275</url>
  </required_header>
  <id_info>
    <org_study_id>DCL-08-001</org_study_id>
    <nct_id>NCT00925275</nct_id>
  </id_info>
  <brief_title>Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Multi-Center, Open-Label, Dosimetry Study of I-131-CLR1404 in Patients With Relapsed or Refractory Advanced Solid Tumors Who Have Failed Standard Therapy or for Whom No Standard Therapy Exists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cellectar, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cellectar, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry&#xD;
      and pharmacokinetics of I-131-CLR1404.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      I-131-CLR1404 is a small-molecule, phospholipid ether analog that combines lipid-like&#xD;
      properties with a cancer therapeutic beta-emitting radioisotope. Cellectar believes that this&#xD;
      compound will benefit individuals with cancer due to its selective retention and accumulation&#xD;
      in malignant cells versus nonmalignant cells. Preclinical experiments have demonstrated that&#xD;
      I-131-CLR1404 significantly slows malignant tumor growth in several mouse tumor models.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Calculate whole body and organ radiation dosimetry of I-131-CLR1404 to determine the millicurie dose which is expected to deliver 35-40 centigray of radiation to bone marrow</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety and pharmacokinetic profile of I-131-CLR1404</measure>
    <time_frame>42 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dosimetric</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I-131-CLR1404</intervention_name>
    <description>Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0</description>
    <arm_group_label>Dosimetric</arm_group_label>
    <other_name>CLR1404</other_name>
    <other_name>1404</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsed or refractory advanced solid tumor(s) and have exhausted standard treatment&#xD;
             options or no standard therapy exists&#xD;
&#xD;
          -  Must have a sufficient window of time to complete the washout period, dosimetry data&#xD;
             acquisition and the follow up safety assessment period&#xD;
&#xD;
          -  ECOG performance status of 0 or 1 and estimated life expectancy of ≥ 4 months&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Must be compliant with the protocol and be within geographical proximity to make the&#xD;
             required study visits&#xD;
&#xD;
          -  Have the ability to read, understand and provide written informed consent&#xD;
&#xD;
          -  Patients with brain metastasis are acceptable if the clinical condition has been&#xD;
             stable for at least one month&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative serum pregnancy test&#xD;
             within 24 hours of start of treatment&#xD;
&#xD;
          -  Must agree to use an effective method of contraception during the study and for 90&#xD;
             days following the last dose of study drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient or physician plans concomitant chemotherapy, therapeutic radiation treatment,&#xD;
             and/or biological treatment for cancer including immunotherapy while on study&#xD;
&#xD;
          -  More than 25% of the total bone marrow irradiated&#xD;
&#xD;
          -  Diffuse lung disease or interstitial spread of carcinoma&#xD;
&#xD;
          -  Bladder or rectum is within a prior radiation therapy field and a dose of greater than&#xD;
             45 Gy was administered&#xD;
&#xD;
          -  Total therapeutic radiation dose in the past year in excess of 25 Gy to the kidney, 45&#xD;
             Gy to brain, 45 Gy to stomach, 18 Gy to lung, or 25 Gy to liver&#xD;
&#xD;
          -  Prior total-body irradiation&#xD;
&#xD;
          -  Extradural tumor in contact with the spinal cord, or tumor located where swelling in&#xD;
             response to therapy may impinge upon the spinal cord&#xD;
&#xD;
          -  Prior radiation therapy or chemotherapy within 2 weeks of the start of the study&#xD;
&#xD;
          -  Active medical condition(s) or organ disease(s) that may either compromise patient&#xD;
             safety or interfere with the safety and/or outcome evaluation of the study drug&#xD;
&#xD;
          -  Laboratory values ≤ 7 days:&#xD;
&#xD;
               -  WBC &lt; 3000/µL&#xD;
&#xD;
               -  Absolute neutrophil count &lt; 1500/µL&#xD;
&#xD;
               -  Platelets &lt; 150,000/µL&#xD;
&#xD;
               -  Hemoglobin ≤ 11.0 gm/dL&#xD;
&#xD;
               -  Total bilirubin &gt; 1.5 x upper limit of normal for age&#xD;
&#xD;
               -  SGOT or SGPT &gt; 3 x upper limit of normal for age if no liver metastases or &gt; 5 x&#xD;
                  upper limit of normal for age in the presence of liver metastases&#xD;
&#xD;
               -  Serum creatinine &gt; 1.5 x upper limit of normal for age&#xD;
&#xD;
               -  INR ≥ 2.0&#xD;
&#xD;
          -  Investigational drug, investigational biologic, or investigational therapeutic device&#xD;
             within 30 days of initiating study drug&#xD;
&#xD;
          -  Severely marrow toxic drugs (e.g. nitrosoureas, mitomycin)&#xD;
&#xD;
          -  Prior treatment with Iodine-131 in the past five years&#xD;
&#xD;
          -  Concurrent hemodialysis&#xD;
&#xD;
          -  Blood transfusions within 60 days of study start&#xD;
&#xD;
          -  Hematopoietic growth factor therapy within 60 days of study start&#xD;
&#xD;
          -  Prior stem cell transplantation&#xD;
&#xD;
          -  Clinically evident ascites or with peritoneal carcinomatosis&#xD;
&#xD;
          -  Clinically significant cardiac co-morbidities including: CHF, a LVEF&lt; 40%, unstable&#xD;
             angina pectoris, serious cardiac arrhythmia requiring medication or a pacemaker,&#xD;
             myocardial infarction within the past six months&#xD;
&#xD;
          -  Clinically significant pulmonary impairment defined as an SaO2 on room air of 93% or&#xD;
             less&#xD;
&#xD;
          -  Concurrent or recent use of thrombolytic agents, or full-dose anticoagulants&#xD;
&#xD;
          -  Uncontrolled hypertension or patients with uncontrolled diabetes&#xD;
&#xD;
          -  Grade II-IV peripheral vascular disease or peripheral vascular surgery within the past&#xD;
             year&#xD;
&#xD;
          -  Less than 4 weeks since prior major surgery&#xD;
&#xD;
          -  Known positive for HIV, Hepatitis C (active, previously treated or both), or is&#xD;
             Hepatitis B core antigen positive&#xD;
&#xD;
          -  Concurrent chronic use of aspirin (325 mg/day or more)&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Patients with colostomy/ileostomy&#xD;
&#xD;
          -  Poor venous access&#xD;
&#xD;
          -  Prior allergic reactions to iodine, or other study agents&#xD;
&#xD;
          -  Significant traumatic injury within the past 4 weeks&#xD;
&#xD;
          -  Ongoing or active infection requiring antibiotics or with a fever &gt;38.1°C (&gt;101° F)&#xD;
             within 3 days of the first scheduled day of dosing&#xD;
&#xD;
          -  Patients who are hospitalized&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Cellectar, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University, Lombardi Cancer Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>June 18, 2009</study_first_submitted>
  <study_first_submitted_qc>June 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2009</study_first_posted>
  <last_update_submitted>April 30, 2010</last_update_submitted>
  <last_update_submitted_qc>April 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director Clinical Operations</name_title>
    <organization>Cellectar, Inc.</organization>
  </responsible_party>
  <keyword>Solid tumors</keyword>
  <keyword>Refractory</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Radiation</keyword>
  <keyword>Dosimetry</keyword>
  <keyword>Radiopharmaceutical</keyword>
  <keyword>Biodistribution</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Cancer</keyword>
  <keyword>Phase I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

